Shares of LightPath Technologies surged 10.4% to $14.49 after Piper Sandler analyst Clarke Jeffries launched coverage with an Overweight rating and a $15 price target, injecting fresh Wall Street credibility into a small-cap optics company that has already returned more than 250% over the past year. The question now: how much of LightPath's promise is already baked into the stock.
• A Rare Street Endorsement Adds Institutional Legitimacy
Piper Sandler analyst Clarke Jeffries initiated coverage on August 12 , joining Canaccord Genuity, which holds a Buy rating with a $16.50 target . LightPath's average analyst price target now sits at $15.78 . For a stock with roughly 56% institutional ownership , a respected mid-cap research shop stepping in can broaden the buyer base — but at $14.49, nearly all of Piper's upside has already evaporated in two days of buying.
• China's Germanium Squeeze Hands LightPath a Pricing Edge The core bull case rests on geopolitics. LightPath holds an exclusive license to a synthetic glass — a germanium substitute — that sidesteps cost spikes from Chinese export controls . Piper Sandler said LightPath now competes at or below germanium pricing . China's germanium ban on U.S. military end-users remains active , meaning defense contractors need alternatives. LightPath has also divested its China business, aligning with U.S. defense procurement rules — a deliberate bet that Pentagon-compliant supply chains will command premium pricing.
• Revenue Is Surging, but Losses Persist
Revenue more than doubled to $19.1 million in fiscal Q3 2026, up 109% year-over-year , driven by acquisitions and infrared camera demand. Backlog hit a record $110.6 million, up 196% . Yet the net loss widened 15% to $4.1 million , partly from acquisition-related charges. Analysts don't expect the company to turn a profit until fiscal 2027 , leaving shareholders funding growth out of a $55 million cash pile from a recent capital raise.
• The Stock May Already Be Pricing In the Good News
Despite the 252% one-year return, at least one valuation model flags LPTH as potentially overvalued at current levels . With next earnings not due until September 24 , investors face a six-week information vacuum. Management's long-term revenue target exceeds $300 million — ambitious for a company running at roughly $70 million annualized. The Piper initiation validates the thesis; the price now demands execution.